BIONET Therapeutics Company Description

BIONET Therapeutics Corp., a biopharmaceutical company, develops regenerative medicine cell preparations for acute and severe diseases.

The company develops treatment for adult respiratory distress syndrome, pulmonary fibrosis, chronic kidney disease, acute wound healing, chronic wound healing of diabetic ulcers, osteoarthritis, and dry eye syndrome.

It also provides mammalian and plant sourced exosomes, and CRDMO services. The company’s pipeline includes BU-01 which is in Phase 2 trail for pulmonary fibrosis and ARDS; and is in phase 1 trials for chronic kidney diseases and chronic wound, as well as ExoTear that is in preclinical trial for the treatment of dry eye.

The company was founded in 2022 and is based in Taipei, Taiwan.

BIONET Therapeutics Corp.

Country	Taiwan
Founded	2022
Industry	Biological Products, Except Diagnostic Substances
Employees	105
CEO	Cheng-Hsien Tsai

Contact Details

Address: No.28, Xinhu 1st Rd. Taipei, 114065 Taiwan
Phone	886 2 2795 1777
Website	bionettx.com

Stock Details

Ticker Symbol	7808
Exchange	Taipei Exchange
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	TWD
SIC Code	2836

Key Executives

Name	Position
Cheng-Hsien Tsai	Chief Executive Officer
Pei Yi Liu	Chief Financial Officer